Ramy G. Seddik

Dr. Ramy G. Seddik

Faculty of Science, Galala University, Suez, As Suways, Egypt
orcid
Open for collaboration

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

11 September 2024 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
Ramy G. SeddikRamy G. Seddik
Ramy G. Seddik
FRFatma B. Rashidi
Fatma B. Rashidi
DSDoaa S. Salah‐Eldin
Doaa S. Salah‐Eldin
ASAzza A. Shoukry
Azza A. Shoukry

17 March 2026 in Journal of Inorganic and Organometallic Polymers and Materials
Verified
Journal Article
Open access
NMNasraldin B. Mohager
Nasraldin B. Mohager
FRFatma B. Rashidi
Fatma B. Rashidi
SHSafaa S. Hassan
Safaa S. Hassan
LALeila M. Abbass
Leila M. Abbass
Ramy G. SeddikRamy G. Seddik
Ramy G. Seddik
KIKhaled M. Ismail
Khaled M. Ismail
Pyrazine, a naturally occurring heterocycle with established safety in food and pharmaceutical applications, is an attractive ligand for the design of platinum-based anticancer agents. In this study, a novel platinum(II) complex, [Pt(Pz) 2 Cl 2 ], was synthesized using pyrazine as a nitrogen-donor ligand. The complex was comprehensively characterized by molar conductivity, elemental analysis, FT-IR, 1 H-NMR, UV–Vis, mass spectrometry, thermal analysis, and magnetic susceptibility. X-ray diffraction confirmed its semicrystalline structure, and TEM revealed irregularly shaped nanoparticles with an average size of 15–20 nm. Biological studies demonstrated strong interaction with DNA, including groove binding and cleavage activity, supported by viscosity measurements and thermal denaturation assays. The complex also exhibited significant binding affinity to bovine serum albumin (BSA), indicating favorable transport and distribution in biological systems. In vitro cytotoxicity assays showed that [Pt(Pz) 2 Cl 2 ] exerted the strongest inhibitory effect on A549 lung cancer cells (IC 50 = 7.97 ± 0.03 µg/mL), followed by HCT-116 colon (IC 50 = 28.22 µg/mL) and HepG2 liver cancer cells (IC 50 = 53.02 µg/mL), while displaying markedly lower toxicity toward normal WI-38 fibroblasts (IC 50 = 235 µg/mL), reflecting selective cytotoxicity. Morphological and flow cytometric analyses confirmed that the complex effectively induces necrotic cell death in A549 cells at concentrations near its IC 50 . Computational studies, including DFT and molecular docking, provided insights into the electronic structure and protein-binding interactions of the complex, while ADME-Tox predictions indicated favorable pharmacokinetic behavior and compliance with drug-likeness rules. Collectively, these findings highlight [Pt(Pz) 2 Cl 2 ] as a promising platinum-based anticancer candidate and reinforce the potential of pyrazine ligands in developing next-generation anticancer therapeutics.

1 January 2017 in General Medicine Open
Verified
Journal Article
Open access
MAMaha A Ali
Maha A Ali
MMMervat S Mohamed
Mervat S Mohamed
Ramy G. SeddikRamy G. Seddik
Ramy G. Seddik
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.

14 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSafaa Said
Safaa Said
FRFatma B. Rashidi
Fatma B. Rashidi
Ramy G. SeddikRamy G. Seddik
Ramy G. Seddik
AEAreej W. El-Sayed
Areej W. El-Sayed
HMHabiba A. Mohamed
Habiba A. Mohamed
KIKhaled M. Ismail
Khaled M. Ismail
Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoconjugate vanadyl complexes as GLUT-directed anticancer agents against breast cancer. A Schiff base ligand (CG) was synthesized through the condensation of curcumin (C) and glucosamine (G), followed by complexation with vanadyl to form [VO(CG)₂]·5H₂O. The synthesized compounds were comprehensively characterized by elemental analysis, MS, NMR, FT-IR, TGA, molar conductance, and magnetic susceptibility measurements. Spectroscopic and computational studies confirmed that the ligand coordinates in a bidentate chelating mode via the azomethine nitrogen and the enolic oxygen. Biological evaluation in MCF-7 breast cancer cells included cytotoxicity assays, molecular docking, DNA-binding studies, and quantitative gene expression analysis. Both compounds exhibited cytotoxic activity, with the CG ligand showing the highest potency (IC₅₀ = 7.51 ± 0.12 μg/mL or 14.2 μM). Notably, co-treatment with the GLUT inhibitor quercetin significantly increased the IC₅₀ value, suggesting the involvement of GLUT-mediated cellular uptake. Molecular docking studies indicated favorable binding affinity toward GLUT, while DNA-binding experiments demonstrated interaction with DNA. Treatment of MCF-7 cells with the glycoconjugate ligand induced DNA damage, modulated the expression of cell cycle- and apoptosis-related genes, and promoted apoptosis. Flow cytometric analysis demonstrated that the glycoconjugate significantly arrested MCF-7 cells in the S-phase (49.40% vs 22.22% in control). This finding is consistent with impaired cell cycle progression and may be associated with the observed DNA interaction. Quantitative real-time PCR analysis of the CG compound revealed significant upregulation of BAX and CDKN1A (p21) ( p ≤ 0.05) and pronounced upregulation of STK11 (LKB1) ( p ≤ 0.001), suggesting activation of the AMPK signaling pathway and a metabolic stress response. Overall, the glycoconjugate ligand induces apoptosis and cell cycle arrest through oxidative and metabolic stress mediated by AMPK–STK11 signaling, highlighting its potential as a GLUT-targeted chemotherapeutic agent for breast cancer treatment.

15 May 2023 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
Ramy G. SeddikRamy G. Seddik
Ramy G. Seddik
DSDoaa S. Salah-Eldin
Doaa S. Salah-Eldin
ASAzza A. Shoukry
Azza A. Shoukry
FRFatma B. Rashidi
Fatma B. Rashidi
To discover other new metal drugs as anticancer therapeutics with low toxicity and high potency, two new palladium (II) complexes of the general formula [Pd(CAZ)Cl2] (1) and [Pd(3-AT)Cl2] (2), (where CAZ is ceftazidime and 3-AT is amitrole) were synthesized and re-characterized by elemental analysis and FT-IR. The Pd(II) complexes were gamma-irradiated with a dose of 30 kGy using Indian 60Co gamma rays and characterized by FT-IR analysis. The inhibitory activity of both complexes before and after irradiation was evaluated against various Gram-positive (G+) and Gram-negative (G−) bacteria and fungi. The antimicrobial properties of both complexes were enhanced by gamma irradiation against (G+) bacteria and fungi. The interaction of the diaqua complexes with CT-DNA was investigated by UV–vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, and molecular docking studies. The calculated intrinsic binding constant (Kb) reveals strong binding interaction with CT-DNA. The binding of complexes is likely via minor groove binding and/or electrostatic interactions. Additionally, spectroscopic, and molecular docking studies analyzed complexes' interaction with BSA (bovine serum albumin). Both complexes also exhibited good binding affinity to BSA. Strong interactions with DNA and BSA suggest that the two complexes could be potential targets for DNA and BSA in biological media. Furthermore, the in vitro cytotoxicity of the complexes against MCF-7 (human breast adenocarcinoma) cell lines, HCT-116 (human colorectal carcinoma) cell lines, and normal HSF (human skin fibroblast) cell lines before and after irradiation were examined by MTT assay. Cytotoxicity assay indicates that the synthesized palladium (II) complexes could be classified as promising cell growth inhibitors against the tested cancer cell lines.